Last reviewed · How we verify
H4:IC31
At a glance
| Generic name | H4:IC31 |
|---|---|
| Sponsor | Aeras |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Safety and Immunogenicity Study of BCG, H4:IC31, and H56:IC31 Revaccination in Healthy Adolescents (PHASE1)
- Evaluation of Safety, Immunogenicity, and Prevention of TB With AERAS-404 and BCG Revaccination in Healthy Adolescents (PHASE2)
- Phase 1/II, Safety and Immunogenicity Study of AERAS-404 in BCG-Primed Infants (PHASE1, PHASE2)
- A Study for Safety and Immunogenicity of BCG and AERAS-404 in HIV-Negative, TB-Negative, BCG-Naive Adults (PHASE1)
- A Phase I Study to Evaluate Safety and Immunogenicity of AERAS 404 (C-011-404) (PHASE1)
- A Phase I Study to Evaluate Safety and Immunogenicity of AERAS 404 Administered in Adults (PHASE1)
- A Phase I Randomized Placebo-Controlled, Double-Blind Study to Evaluate Safety and Immunogenicity of AERAS-404 Administered as Different Amounts of Antigen and Adjuvant Combinations in HIV-Negative BCG-Vaccinated Adults Without Evidence of Tuberculosis Infection (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- H4:IC31 CI brief — competitive landscape report
- H4:IC31 updates RSS · CI watch RSS
- Aeras portfolio CI